Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

NCT05542342 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Uveal Melanoma

Interventions

DRUG: Tislelizumab
DRUG: Sitravatinib Malate

Sponsor

Grupo Español Multidisciplinar de Melanoma

Collaborators

[object Object]
[object Object]